blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1817051

EP1817051 - PHARMACEUTICAL COMPOSITIONS COMPRISING BOTULINUM NEUROTOXIN, A NON IONIC SURFACTANT, SODIUM CHLORIDE AND SUCROSE [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  08.03.2024
Database last updated on 22.08.2024
Most recent event   Tooltip08.03.2024Patent maintained (B2 publication)published on 10.04.2024  [2024/15]
Applicant(s)For all designated states
Ipsen Biopharm Limited
Ash Road, Wrexham Industrial Estate
Wrexham LL13 9UF / GB
[2024/15]
Former [2010/26]For all designated states
Ipsen Biopharm Limited
Ash Road, Wrexham Industrial Estate
Wrexham LL13 9UF / GB
Former [2009/50]For all designated states
Ipsen Developments Limited
190 Bath Road Slough
Berkshire SL1 3XE / GB
Former [2007/33]For all designated states
Ipsen Limited
190 Bath Road Slough
Berkshire SL1 3XE / GB
Inventor(s)01 / WEBB, Paul
Ipsen Biopharm
Unit 9, Ash Road
Wrexham Industrial Estate
Wrexham LL13 9UF / GB
02 / WHITE, Mary
Ipsen Biopharm
Unit 9, Ash Road
Wrexham Industrial Estate
Wrexham LL13 9UF / GB
03 / PARTINGTON, Julie
Ipsen Biopharm
Unit 9, Ash Road
Wrexham Industrial Estate
Wrexham LL13 9UF / GB
 [2014/42]
Former [2007/33]01 / WEBB, Paul, Ipsen Biopharm
Unit 9, Ash Road, Wrexham Industrial Estate
Wrexham LL13 9UF / GB
02 / WHITE, Mary, Ipsen Biopharm
Unit 9, Ash Road, Wrexham Industrial Estate
Wrexham LL13 9UF / GB
03 / PARTINGTON, Julie, Ipsen Biopharm
Unit 9, Ash Raod, Wrexham Industrial Estate
Wrexham LL13 9UF / GB
Representative(s)Plasseraud IP
104 Rue de Richelieu
CS92104
75080 Paris Cedex 02 / FR
[N/P]
Former [2024/15]Plasseraud IP
66, rue de la Chaussée d'Antin
75440 Paris Cedex 09 / FR
Former [2009/50]Retzler, Charlotte, et al
Ipsen Pharma Direction Propriété Intellectuelle 65, quai Georges Gorse
92650 Boulogne Billancourt Cedex / FR
Former [2007/33]Davies, Jonathan Mark
Reddie & Grose 16 Theobalds Road
London WC1X 8PL / GB
Application number, filing date05757842.906.07.2005
[2007/33]
WO2005GB02653
Priority number, dateGB2004001549112.07.2004         Original published format: GB 0415491
[2007/33]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006005910
Date:19.01.2006
Language:EN
[2006/03]
Type: A2 Application without search report 
No.:EP1817051
Date:15.08.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 19.01.2006 takes the place of the publication of the European patent application.
[2007/33]
Type: B1 Patent specification 
No.:EP1817051
Date:25.02.2015
Language:EN
[2015/09]
Type: B2 New European patent specification 
No.:EP1817051
Date:10.04.2024
Language:EN
[2024/15]
Search report(s)International search report - published on:EP14.09.2006
ClassificationIPC:A61K38/48, A61K47/30
[2007/33]
CPC:
A61K9/0019 (EP,US); A61K38/4886 (EP,US); A61K38/4893 (EP,US);
A61K47/02 (US); A61K47/183 (US); A61K47/22 (US);
A61K47/26 (EP,US); A61K9/19 (EP,US); A61P1/00 (EP);
A61P11/00 (EP); A61P13/00 (EP); A61P13/02 (EP);
A61P15/00 (EP); A61P17/00 (EP,US); A61P17/02 (EP);
A61P19/02 (EP); A61P21/00 (EP); A61P21/02 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P25/06 (EP);
A61P25/08 (EP); A61P25/16 (EP); A61P27/02 (EP);
A61P29/00 (EP); A61P3/04 (EP); A61P3/10 (EP);
A61P35/00 (EP); A61P37/06 (EP); A61P5/00 (EP);
C12Y304/24069 (EP,US); Y02A50/30 (EP,US) (-)
C-Set:
A61K38/4886, A61K2300/00 (EP);
A61K38/4893, A61K47/26 (US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2024/15]
Former [2007/33]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL09.02.2007
HR09.02.2007
MK09.02.2007
YU09.02.2007
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG, ENTHALTEND BOTULINUM NEUROTOXIN, EIN NICHTIONISCHES TENSID, NATRIUMCHLORID UND SACCHAROSE[2014/30]
English:PHARMACEUTICAL COMPOSITIONS COMPRISING BOTULINUM NEUROTOXIN, A NON IONIC SURFACTANT, SODIUM CHLORIDE AND SUCROSE[2007/33]
French:COMPOSITION PHARMACEUTIQUE CONTENANT DE LA NEUROTOXINE BOTULIQUE[2007/33]
Former [2007/33]PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT BOTULINUM NEUROTOXIN, EINEM NICHTIONISCHEN TENSID, NATRIUMCHLORID UND SACCHAROSE
Entry into regional phase09.02.2007National basic fee paid 
09.02.2007Designation fee(s) paid 
09.02.2007Examination fee paid 
Examination procedure13.06.2006Request for preliminary examination filed
International Preliminary Examining Authority: EP
09.02.2007Examination requested  [2007/33]
08.05.2008Despatch of a communication from the examining division (Time limit: M04)
08.09.2008Reply to a communication from the examining division
09.02.2012Despatch of a communication from the examining division (Time limit: M04)
18.06.2012Reply to a communication from the examining division
25.04.2013Despatch of a communication from the examining division (Time limit: M04)
03.09.2013Reply to a communication from the examining division
26.11.2013Despatch of a communication from the examining division (Time limit: M04)
07.03.2014Reply to a communication from the examining division
23.09.2014Communication of intention to grant the patent
09.01.2015Fee for grant paid
09.01.2015Fee for publishing/printing paid
09.01.2015Receipt of the translation of the claim(s)
Divisional application(s)EP10010686.3  / EP2269631
EP15000178.2  / EP2939688
EP18185827.5  / EP3446701
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.05.2008
Opposition(s)Opponent(s)01  20.11.2015  25.11.2015  ADMISSIBLE
Merz Pharma GmbH & Co. KGaA
Eckenheimer Landstrasse 100
60318 Frankfurt/Main / DE
Opponent's representative
Graf Keyserlingk, Nikolai
Merz Therapeutics GmbH
Patent Affairs
Eckenheimer Landstraße 100
60318 Frankfurt am Main / DE
 02  24.11.2015  01.12.2015  ADMISSIBLE
ALLERGAN, INC.
2525 Dupont Drive
Irvine CA 92612 / US
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 03  24.11.2015  04.12.2015  ADMISSIBLE
Daewoong Pharmaceutical Co., Ltd.
Bongeunsa-ro 114-gil 12
Gangnam-gu
Seoul / KR
Opponent's representative
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 [N/P]
Former [2024/03]
Opponent(s)01  20.11.2015  25.11.2015  ADMISSIBLE
Merz Pharma GmbH & Co. KGaA
Eckenheimer Landstrasse 100
60318 Frankfurt/Main / DE
Opponent's representative
Graf Keyserlingk, Nikolai
Merz Therapeutics GmbH
Patent Affairs
Eckenheimer Landstraße 100
60318 Frankfurt am Main / DE
 02  24.11.2015  01.12.2015  ADMISSIBLE
ALLERGAN, INC.
2525 Dupont Drive
Irvine CA 92612 / US
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 03  24.11.2015  04.12.2015  ADMISSIBLE
Daewoong Pharmaceutical Co., Ltd.
Bongeunsa-ro 114-gil 12
Gangnam-gu
Seoul / KR
Opponent's representative
Kraus & Weisert Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Former [2022/28]
Opponent(s)01  20.11.2015  25.11.2015  ADMISSIBLE
Merz Pharma GmbH & Co. KGaA
Eckenheimer Landstrasse 100
60318 Frankfurt/Main / DE
Opponent's representative
Graf Keyserlingk, Nikolai
Merz Therapeutics GmbH
Patent Affairs
Eckenheimer Landstraße 100
60318 Frankfurt am Main / DE
 02  24.11.2015  01.12.2015  ADMISSIBLE
ALLERGAN, INC.
2525 Dupont Drive
Irvine CA 92612 / US
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 03  24.11.2015  04.12.2015  ADMISSIBLE
Daewoong Pharmaceutical Co., Ltd.
Bongeunsa-ro 114-gil 12
Gangnam-gu
Seoul / KR
Opponent's representative
Ladendorf, Oliver
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Former [2016/01]
Opponent(s)01  20.11.2015  25.11.2015  ADMISSIBLE
Merz Pharma GmbH & Co. KGaA
Eckenheimer Landstrasse 100
60318 Frankfurt/Main / DE
Opponent's representative
Graf Keyserlingk, Nikolai
Merz Pharma GmbH & Co. KGaA
Patent Affairs
Eckenheimer Landstraße 100
60318 Frankfurt am Main / DE
 02  24.11.2015  01.12.2015  ADMISSIBLE
ALLERGAN, INC.
2525 Dupont Drive
Irvine CA 92612 / US
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 03  24.11.2015    ADMISSIBLE
Daewoong Pharmaceutical Co., Ltd.
Bongeunsa-ro 114-gil 12
Gangnam-gu
Seoul / KR
Opponent's representative
Ladendorf, Oliver
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Former [2016/01]
Opponent(s)01  20.11.2015  25.11.2015  ADMISSIBLE
Merz Pharma GmbH & Co. KGaA
Eckenheimer Landstrasse 100
60318 Frankfurt/Main / DE
Opponent's representative
Graf Keyserlingk, Nikolai
Merz Pharma GmbH & Co. KGaA
Patent Affairs
Eckenheimer Landstraße 100
60318 Frankfurt am Main / DE
08.01.2016Invitation to proprietor to file observations on the notice of opposition
09.05.2016Reply of patent proprietor to notice(s) of opposition
25.11.2021Despatch of a communication from the opposition division (Time limit: M04)
15.03.2022Reply to a communication from the opposition division
15.09.2022Despatch of a communication from the opposition division (Time limit: M02)
27.07.2023Despatch of interlocutory decision in opposition
06.08.2023Legal effect of interlocutory decision in opposition
14.11.2023Despatch of communication that the patent will be maintained as amended
02.02.2024Fee for printing new specification paid
Appeal following opposition26.06.2018Appeal received No.  T1483/18
27.08.2018Statement of grounds filed
18.06.2021Result of appeal procedure: maintenance in amended form
05.08.2021Despatch of the decision of the Board of Appeal
12.06.2018Appeal received No.  T1483/18
27.08.2018Statement of grounds filed
18.06.2021Result of appeal procedure: maintenance in amended form
05.08.2021Despatch of the decision of the Board of Appeal
27.11.2017Date of oral proceedings
16.04.2018Minutes of the oral proceedings despatched
18.06.2021Date of oral proceedings
Fees paidRenewal fee
09.02.2007Renewal fee patent year 03
14.07.2008Renewal fee patent year 04
10.07.2009Renewal fee patent year 05
14.07.2010Renewal fee patent year 06
01.08.2011Renewal fee patent year 07
31.07.2012Renewal fee patent year 08
31.07.2013Renewal fee patent year 09
31.07.2014Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG25.02.2015
CY25.02.2015
EE25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
SI25.02.2015
SK25.02.2015
IS25.06.2015
LU06.07.2015
[2017/39]
Former [2016/15]EE25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
SI25.02.2015
SK25.02.2015
IS25.06.2015
LU06.07.2015
Former [2016/13]EE25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
SI25.02.2015
SK25.02.2015
IS25.06.2015
Former [2016/12]EE25.02.2015
LT25.02.2015
LV25.02.2015
SI25.02.2015
SK25.02.2015
IS25.06.2015
Former [2015/49]EE25.02.2015
LT25.02.2015
LV25.02.2015
SK25.02.2015
IS25.06.2015
Former [2015/39]LT25.02.2015
LV25.02.2015
IS25.06.2015
Former [2015/38]LT25.02.2015
IS25.06.2015
Former [2015/35]LT25.02.2015
Cited inInternational search[X]US2003118598  (HUNT TERRENCE J [US]);
 [X]WO2004006954  (ALLERGAN INC [US], et al);
 [X]US2004033241  (DONOVAN STEPHEN [US]);
 [X]WO2004043430  (ALLERGAN INC [US], et al);
 [E]WO2006013357  (IPSEN LTD [GB], et al);
 [E]WO2006013370  (IPSEN LTD [GB], et al)
by applicantWO9611699
 US5512547
 WO9735604
 US5756468
 WO0158472
OppositionWO9937326
 WO0158472
 US2003118598
 US2003138437
 WO2005007185
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.